Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): A randomised controlled trial

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): A randomised controlled trial

Show other versions (1)

Background: Metformin reduces cardiovascular risk in patients with type 2 diabetes seemingly independent of lowering blood glucose concentration. We assessed the cardiovascular effects of metformin in individuals without type 2 diabetes. Methods: We did a single-centre, double-blind, placebo-control...

Full description

Bibliographic Details
Main Authors:	Preiss, D, Lloyd, S, Ford, I, McMurray, J, Holman, R, Welsh, P, Fisher, M, Packard, C, Sattar, N
Format:	Journal article
Language:	English
Published:	2014

Similar Items

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
by: Preiss, D, et al.
Published: (2014)

Metformin therapy and circulating NT-proBNP levels: the CAMERA trial
by: Preiss, D, et al.
Published: (2016)

Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study: Metabolism
by: Preiss, D, et al.
Published: (2016)

Putative miRNA biomarkers of insulin resistance and the effect of metformin: data from the CAMERA trial
by: ALRamah, T, et al.
Published: (2017)

Associations of targeted circulating microRNAs with insulin resistance in the CAMERA (Carotid Atherosclerosis: MEtformin for insulin ResistAnce) trial
by: Alramah, T, et al.
Published: (2019)

The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes
by: Preiss, D, et al.
Published: (2016)

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
by: McMurray, J, et al.
Published: (2014)

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
by: Wamil, M, et al.
Published: (2020)

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
by: Holman, R, et al.
Published: (2017)

Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure
by: Preiss, D, et al.
Published: (2016)

Research digest: CV trials in diabetes — Looking ahead
by: Preiss, D, et al.
Published: (2018)

Myoinositol and Metformin versus Only Metformin in the Management of Gestational Diabetes Mellitus: A Randomised Open-label Clinical Trial
by: Palash Mazumder, et al.
Published: (2023-04-01)

METFORMIN IN THE MANAGEMENT OF TYPE-2 DIABETES - REPLY
by: Holman, R, et al.
Published: (1989)

Metformin as first choice in oral diabetes treatment: the UKPDS experience.
by: Holman, R
Published: (2007)

Increased risk of incident heart failure and all-cause mortality in insulin-resistant people with type 2 diabetes in the United Kingdom Prospective Diabetes Study (UKPDS)
by: Wamil, M, et al.
Published: (2020)

Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future.
by: Rankin, N, et al.
Published: (2016)

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
by: Stevens, R, et al.
Published: (2012)

Effect of Valsartan on the Incidence of Diabetes REPLY
by: Holman, R, et al.
Published: (2010)

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.
by: Rémy Boussageon, et al.
Published: (2012-01-01)

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.
by: Preiss, D, et al.
Published: (2014)

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
by: Kristensen, SL, et al.
Published: (2019)

Prediabetes and the risk of diabetes.
by: McMurray, J, et al.
Published: (2012)

Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89
by: Wamil, M, et al.
Published: (2021)

UKPDS - 6-YEAR TRIAL OF SULFONYLUREA, INSULIN AND METFORMIN THERAPY IN TYPE-2 DIABETIC-PATIENTS WITH DIET FAILURE
by: Cull, C, et al.
Published: (1995)

Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease
by: Schwartz, GG, et al.
Published: (2020)

Framingham risk equations underestimate coronary heart disease risk in diabetes.
by: Stevens, R, et al.
Published: (2005)

UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
by: Wright, A, et al.
Published: (1998)

Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial
by: Mauro Chiarito, et al.
Published: (2023-02-01)

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
by: Sattar, N, et al.
Published: (2016)

Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation
by: Basil Alnasrallah, et al.
Published: (2019-04-01)

Metformin and Bee Venom Enhanced Histological Changes of the Pancreas in Diabetic Mice
by: Rana, et al.
Published: (2022-09-01)

Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction
by: John McMurray, et al.
Published: (2000-06-01)

Plasma homocysteine, type 2 diabetes and risk of coronary heart disease in the UKPDS
by: Holman, R, et al.
Published: (2001)

Change in levels of physical activity after diagnosis of type 2 diabetes: An observational analysis from the NAVIGATOR study
by: Preiss, D, et al.
Published: (2014)

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT
by: Griffin, SJ, et al.
Published: (2018)

Comparison of Nisha-amalaki and Metformin in Overweight and Obese Patients with Type 2 Diabetes Mellitus (Madhumeha): A Randomised Controlled Trial
by: Aman Chhabra, et al.
Published: (2024-03-01)

Risk factors for coronary heart disease in non-insulin dependent diabetic subjects
by: Turner, R, et al.
Published: (1996)

Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials
by: Goldie, C, et al.
Published: (2016)

Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm
by: Jonathan Golledge, et al.
Published: (2021-12-01)

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT
by: Simon J Griffin, et al.
Published: (2018-04-01)